Page last updated: 2024-11-11

ono4819

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ONO4819: prostanoid receptor EP4 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9803828
CHEMBL ID303960
CHEBI ID168543
SCHEMBL ID2309978
MeSH IDM0469116

Synonyms (28)

Synonym
CHEBI:168543
256382-08-8
methyl 4-[2-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulanyl]butanoate
ono4819
methyl 4-[2-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoate
gtpl1930
rivenprost
ono-ae1-734
ono-4819.cd
ono-4819
ae1-734
CHEMBL303960 ,
(-)-ono-4819
4-(2-{(1r,2r,3r)-3-hydroxy-2-[(e)-(s)-3-hydroxy-4-(3-methoxymethyl-phenyl)-but-1-enyl]-5-oxo-cyclopentyl}-ethylsulfanyl)-butyric acid methyl ester
methyl 4-(2-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxy-4-(3-(methoxymethyl)phenyl)but-1-enyl)-5-oxocyclopentyl)ethylthio)butanoate
bdbm50318871
ono-4819cd
unii-1wbo45t413
1wbo45t413 ,
methyl 4-((2-((1r,2r,3r)-3-hydroxy-2-((1e,3s)-3-hydroxy-4-(3-(methoxymethyl)phenyl)but-1-en-1-yl)-5-oxocyclopentyl)ethyl)sulfanyl)butanoate
rivenprost [inn]
406692-60-2
SCHEMBL2309978
AKOS027326542
methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e)-(3s)-3-hydroxy-4-(m-methoxymethylphenyl)1-butenyl]-5-oxocyclopentyl]-5-thiaheptanoate
Q27088555
methyl 4-[[2-[(1r,2r,3r)-3-hydroxy-2-[(1e,3s)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl]-5-oxocyclopentyl]ethyl]thio]butanoate
DTXSID601101764
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzyl etherA compound of formula PhCH2OR (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E2 receptor EP3 subtypeMus musculus (house mouse)Ki0.05600.00500.01350.0560AID482740
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E2 receptor EP4 subtypeMus musculus (house mouse)EC50 (µMol)0.00160.00160.00250.0036AID482741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID482743Induction of bone formation in mouse assessed as increase in bone mineral content at 300 ug/kg administered into dorsal muscle pouch relative to control2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID482741Agonist activity at mouse EP4 receptor expressed in CHO cells assessed as cAMP production2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID482740Binding affinity to mouse EP3 receptor by competitive binding assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID196491Suppression of production of plasma TNF-alpha after intravenous infusion of 10, 30, 100 and 300 ng/kg/min; significant2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID482742Induction of bone formation in ovariectomized rat assessed as trabecular bone mineral content at 3 ug/kg, sc BID for 11 weeks (RVb = 200 mg/cm3)2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID176652Stimulation of Uterine motility which mediates the EP3-receptor in rats2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID1346336Mouse EP3 receptor (Prostanoid receptors)2002Proceedings of the National Academy of Sciences of the United States of America, Apr-02, Volume: 99, Issue:7
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
AID1346307Mouse EP4 receptor (Prostanoid receptors)2002Proceedings of the National Academy of Sciences of the United States of America, Apr-02, Volume: 99, Issue:7
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
AID1346303Mouse EP2 receptor (Prostanoid receptors)2002Proceedings of the National Academy of Sciences of the United States of America, Apr-02, Volume: 99, Issue:7
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (69.57)29.6817
2010's6 (26.09)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews2 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (86.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]